Build status - In Progress

AGIOS

AGIOS
Enrolling By Invitation
18 years - 99 years
All
Phase 3
5 participants needed
1 Location

Brief description of study


 This research study is a phase 3, double-blind clinical trial to assess the efficacy of Agios versus placebo in subjects with residual or recurrent Grade 2 oligodendroglioma and astrocytoma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment.

Penn Medicine patients that have residual or recurrent non-enhancing Grade 2 glioma (a type of brain cancer) that has an isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) mutation, will be invited to participate.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: oligodendroglioma
  • Age: 18 years - 99 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 843451
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research